A carregar...

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada

OBJECTIVE: Monoclonal antibodies (MAbs) such as trastuzumab and bevacizumab have become important yet expensive components of systemic cancer therapy across a variety of disease sites. We assessed the potential cost implications of adopting trastuzumab and bevacizumab therapy in the context of their...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Drucker, A., Skedgel, C., Virik, K., Rayson, D., Sellon, M., Younis, T.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2442764/
https://ncbi.nlm.nih.gov/pubmed/18596891
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!